Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
42 hedge funds and large institutions have $118M invested in Evelo Biosciences, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 2 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
0% more funds holding
Funds holding: 42 → 42 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
33% less capital invested
Capital invested by funds: $175M → $118M (-$57.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$747K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$165K |
| 3 |
Renaissance Technologies
New York
|
+$82.2K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$42.2K |
| 5 |
State Street
Boston,
Massachusetts
|
+$42.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.39M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$559K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$378K |
| 4 |
HSBC Holdings
London,
United Kingdom
|
-$144K |
| 5 |
Morgan Stanley
New York
|
-$107K |
EVLO Hedge Fund Activity: Q4 2019 in Review
42 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q4 2019, worth a combined $118M — down 33% from $175M a quarter earlier.
Fund positioning in EVLO was balanced in Q4 2019: 2 funds opened new positions, 2 closed out, 16 added to existing stakes and 12 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $747K. The largest seller was Samsara BioCapital, exiting entirely with an estimated $1.39M sold.
- 42 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $118M of Evelo Biosciences, Inc. Common Stock stock for Q4 2019, down 33% quarter-over-quarter.
- 2 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q4 2019 and 2 closed out, a net change of 0 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q4 2019 was Bridgeway Capital Management, an estimated $747K added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q4 2019 was Samsara BioCapital, an estimated $1.39M sold.
Based on aggregated 13F filings for Q4 2019.